NKGen rises on clearance to start mid-stage study on Alzheimer's therapy
20/05/2024 13:35
** Shares of drug developer NKGen Biotech NKGN.O rise
40.2% to $1.58 premarket
** Co says its safety review committee allowed a start on
its mid-stage study on its cell therapy for Alzheimer's disease
** NKGN expects its first patient to be enrolled in Q2
** In an early-stage trial, the therapy SNK01 showed
improvement or maintained stable cognitive function in 90% of
patients
** Up to last close, stock down 59.3% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Recent news on Nkgen Biotech
See all newsBrief: Nkgen Biotech Expands Clinical Trial Site Network For Alzheimer’S Disease Program Across US
Brief: NKgen Biotech And Hekabio Enter Into Strategic Partnership
Brief: Nkgen Biotech Announces International And U.S. Expansion Of Phase 1/2A Troculeucel Alzheimer’S Trial
Brief: Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program
Brief: NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program